{"id":10536,"date":"2020-08-13T17:46:13","date_gmt":"2020-08-13T12:16:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10536"},"modified":"2021-07-24T12:58:03","modified_gmt":"2021-07-24T07:28:03","slug":"recent-pharma-happenings-for-gilead-roche-celleron-f2g","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g","title":{"rendered":"Gilead&#8217;s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche&#8217;s  cancer drug"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0d2220f3d35\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0d2220f3d35\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g\/#Researchers_call_out_Gilead_over_the_diversity_of_remdesivir_trials\" >Researchers call out Gilead over the diversity of remdesivir trials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g\/#Roche_offloads_clinical-phase_cancer_drug_to_Celleron\" >Roche offloads clinical-phase cancer drug to Celleron<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g\/#F2G_raises_USD_608_Million_for_late-phase_antifungal_R_D\" >F2G raises USD 60.8 Million for late-phase antifungal R&amp;D<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g\/#Protein_implication_in_Alzheimers_could_enhance_cancer_immunotherapy\" >Protein implication in Alzheimer\u2019s could enhance cancer immunotherapy<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Researchers_call_out_Gilead_over_the_diversity_of_remdesivir_trials\"><\/span><strong>Researchers call out Gilead over the diversity of remdesivir trials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Researchers have challenged the sponsors of <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\"><strong>COVID-19 clinical trials<\/strong><\/a> to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Black, Latinx, and Native Americans.<\/p>\n\n\n\n<p>The researchers cite data in the New England Journal of Medicine, showing Black Americans account for a disproportionate number of COVID-19 cases in the U.S. In Alabama, Black or African American people report 27% of the population but account for 43% of cases. Hispanic or Latino people are also over-represented in COVID-19 case data in Alabama and other states.<\/p>\n\n\n\n<p>The data hint approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\"><strong>COVID-19 drugs<\/strong><\/a> will be used extensively in Black, Latinx, and Native Americans. However, the researchers found data supporting the efficacy and safety of remdesivir, which is an early <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-therapeutic-pipeline-vaccines\"><strong>COVID-19 drug<\/strong><\/a>, in minority groups are limited.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_offloads_clinical-phase_cancer_drug_to_Celleron\"><\/span><strong>Roche offloads clinical-phase cancer drug to Celleron<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche has transferred its anti-CSF1R monoclonal antibody emactuzumab to Celleron Therapeutics. The licensing agreement comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies in solid tumor patients.<\/p>\n\n\n\n<p>Emactuzumab, which is also known as RG7155 and RO5509554, entered the clinic back in 2011. Roche went on to study the molecule in combination with other assets covering checkpoint inhibitor Tecentriq in solid tumor patients. Roche was preparing to commence another combination trial in <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-market\"><strong>lymphoma <\/strong><\/a>patients when it withdrew the study before enrolling in the first subject in 2018.<\/p>\n\n\n\n<p>Roche called the action as a business decision and accentuating that there were no safety or efficacy concerns. Even so, the decision marked the end of the interest of Roche in developing the asset.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"F2G_raises_USD_608_Million_for_late-phase_antifungal_R_D\"><\/span><strong>F2G raises USD 60.8 Million for late-phase antifungal R&amp;D<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>F2G has raised USD 60.8 million to fund late-phase clinical development of its antifungal agent olorofim and gear up commercialization. The Cowen Healthcare Investments-led round comes four years later F2G raised a similar sum to get the dihydroorotate dehydrogenase inhibitor into phase 2b.<\/p>\n\n\n\n<p>The treatment of fungal infections took a significant step forward two decades ago when the FDA approved Cancidas of Merck, the first drug in a new class of antifungals known as echinocandins. Since then, physicians have had to try for the treatment of fungal infections by using the same core therapeutic toolkit that features three major classes of drugs, including echinocandins.<\/p>\n\n\n\n<p>F2G intends to add to the toolkit. Olorofim, also known as F901318, is part of a new class of antifungal drugs, the orotomides. The drug prevents the dihydroorotate dehydrogenase enzyme from disrupting the synthesis of pyrimidines, compounds that are vital to fungi.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Protein_implication_in_Alzheimers_could_enhance_cancer_immunotherapy\"><\/span><strong>Protein implication in Alzheimer\u2019s could enhance cancer immunotherapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Variants of TREM2, a receptor that is expressed by immune cells, have been linked to the development of <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><strong>Alzheimer\u2019s disease<\/strong><\/a>. Now, scientists have elucidated a potential use for the protein in cancer treatment.<\/p>\n\n\n\n<p>TREM2, which is also found in tumor-infiltrating myeloid cells that sometimes create an immunosuppressive environment, which aids tumors to get away from immune surveillance. A team at Washington University School of Medicine in St. Louis showed, in a study published in Cell, aiming the protein could be a potential new way to boost the power of immuno-oncology drugs.<\/p>\n\n\n\n<p>According to the team, in tumor-bearing mice, treatment with an anti-TREM2 monoclonal antibody, combined with a PD-1 inhibitor, worked better at monitoring tumor growth than either drug alone.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Black, Latinx, and Native Americans. The researchers cite data [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10555,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17629,18652,10830,18651,1393,420,16756,524],"industry":[17225],"therapeutic_areas":[17229,17231,17245,17243],"class_list":["post-10536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-celleron","tag-covid-19","tag-f2g","tag-gilead-sciences","tag-news","tag-remdesivir","tag-roche","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-infectious-diseases","therapeutic_areas-neurology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gilead&#039;s remdesivir; F2G bags $60.8M; Celleron&#039;s pact; Cancer research<\/title>\n<meta name=\"description\" content=\"Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead&#039;s remdesivir; F2G bags $60.8M; Celleron&#039;s pact; Cancer research\" \/>\n<meta property=\"og:description\" content=\"Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-08-13T12:16:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/13174235\/Researchers-call-out-Gilead-over-the-diversity-of-remdesivir-trials.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead's remdesivir; F2G bags $60.8M; Celleron's pact; Cancer research","description":"Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g","og_locale":"en_US","og_type":"article","og_title":"Gilead's remdesivir; F2G bags $60.8M; Celleron's pact; Cancer research","og_description":"Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-08-13T12:16:13+00:00","article_modified_time":"2021-07-24T07:28:03+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/13174235\/Researchers-call-out-Gilead-over-the-diversity-of-remdesivir-trials.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g","name":"Gilead's remdesivir; F2G bags $60.8M; Celleron's pact; Cancer research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/13174235\/Researchers-call-out-Gilead-over-the-diversity-of-remdesivir-trials.gif","datePublished":"2020-08-13T12:16:13+00:00","dateModified":"2021-07-24T07:28:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead\u2019s remdesivir..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-roche-celleron-f2g#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/13174235\/Researchers-call-out-Gilead-over-the-diversity-of-remdesivir-trials.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/13174235\/Researchers-call-out-Gilead-over-the-diversity-of-remdesivir-trials.gif","width":772,"height":482,"caption":"recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/08\/13174235\/Researchers-call-out-Gilead-over-the-diversity-of-remdesivir-trials-300x187.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Celleron<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">F2G<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">gilead sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">remdesivir<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/span>","<span class=\"advgb-post-tax-term\">Celleron<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">F2G<\/span>","<span class=\"advgb-post-tax-term\">gilead sciences<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">remdesivir<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 13, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 13, 2020 5:46 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10536"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10536\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10555"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10536"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10536"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}